Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Intralytix and Ferring Pharmaceuticals Collaborate In Novel Bacteriophage-Based IBD Drug Development Project
Intralytix, Inc., announced today that it has entered into a collaboration agreement with Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group headquartered in St. Prex, Switzerland.
Intralytix Receives Additional Regulatory Approval For ListShield™ - Phage-Based Food Safety Product Effective Against Listeria monocytogenes
Intralytix, Inc. announced today that its food safety product, ListShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).
Intralytix Wins USDA Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogen, Vibrio tubiashii
Intralytix, Inc. announced today that the company has received a SBIR Phase I grant from the U.S. Department of Agriculture (U.S.D.A.) to develop a bacteriophage (or phage) cocktail effective against the shellfish pathogen Vibrio tubiashii.